匹多莫德口服溶液联合布地奈德气雾剂治疗小儿反复性呼吸道感染的临床研究
|
摘要
目的观察匹多莫德口服溶液联合布地奈德气雾剂治疗小儿反复性呼吸道感染(RRTI)的临床疗效及安全性。方法将114例RRTI患儿随机分为对照组和试验组,每组57例。对照组予以匹多莫德初始剂量每次400 mg,bid,治疗10 d后,调整为每次400 mg,qd,口服。试验组在对照组治疗的基础上,予以布地奈德每次100μg,q 6~8 h,吸入给药。2组患儿均持续治疗2个月。比较2组患儿的临床疗效,C反应蛋白(CRP)和T淋巴细胞亚群的水平,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为92.98%(53例/57例)和78.95%(45例/57例),复发率分别为8.77%(5例/57例)和33.33%(19例/57例),差异均有统计学意义(均P<0.05)。治疗后,试验组和对照组的CRP分别为(8.15±2.67)和(12.04±3.08)mg·L~(-1),CD4~+分别为(42.53±3.29)%和(36.48±3.19)%,CD8~+分别为(32.07±3.27)%和(27.81±3.10)%,差异均有统计学意义(均P<0.05)。2组患儿治疗期间均未出现药物不良反应。结论匹多莫德口服溶液联合布地奈德气雾剂治疗小儿RRTI的临床疗效确切,其能显著提高患儿的免疫功能,且安全性较高。
Objective To observe the clinical efficacy and safety of pidotimod oral sodution combined with budesonide pressurised inhalation in the treatment of children with recurrent respiratory tract infection( RRTI). Methods A total of 114 children with RRTI were randomly divided into control and treatment groups with 57 cases per group. Control group was treated with an initial dose of pidotimod at 400 mg per time,bid,and after 10 days' treatment,the dose was adjusted to 400 mg per time,qd,orally. Treatment group was treated with budesonide100 μg per time,q 6-8 h,inhalation administration,on the basis of control group. Two groups were treated for 2 months. The clinical efficacy,C reactive protein( CRP) and T lymphocyte subsets,and adverse drug reactions were compared between two groups. Results After treatment,the total effective rates of treatment and control groups were92. 98%( 53 cases/57 cases) and 78. 95%( 45 cases/57 cases),the recurrence rates were 8. 77%( 5 cases/57 cases) and 33. 33%( 19 cases/57 cases),the differences were statistically significant( all P < 0. 05).After treatment,the main indexes of treatment and control groups werecompared: CRP were( 8. 15 ± 2. 67) and( 12. 04 ± 3. 08) mg·L~(-1),CD4~+were( 42. 53 ± 3. 29) % and( 36. 48 ± 3. 19) %,CD8~+were( 32. 07 ± 3. 27) % and( 27. 81 ± 3. 10) %,the differences were statistically significant( all P < 0. 05). There were no adverse reactions occurred during the treatment. Conclusion Pidotimod oral sodution combined with budesonide pressurised inhalation has a definitive clinical efficacy and safety in the treatment of children with RRTI,which can significantly improve the immune function of the children.
Objective To observe the clinical efficacy and safety of pidotimod oral sodution combined with budesonide pressurised inhalation in the treatment of children with recurrent respiratory tract infection( RRTI). Methods A total of 114 children with RRTI were randomly divided into control and treatment groups with 57 cases per group. Control group was treated with an initial dose of pidotimod at 400 mg per time,bid,and after 10 days' treatment,the dose was adjusted to 400 mg per time,qd,orally. Treatment group was treated with budesonide100 μg per time,q 6-8 h,inhalation administration,on the basis of control group. Two groups were treated for 2 months. The clinical efficacy,C reactive protein( CRP) and T lymphocyte subsets,and adverse drug reactions were compared between two groups. Results After treatment,the total effective rates of treatment and control groups were92. 98%( 53 cases/57 cases) and 78. 95%( 45 cases/57 cases),the recurrence rates were 8. 77%( 5 cases/57 cases) and 33. 33%( 19 cases/57 cases),the differences were statistically significant( all P < 0. 05).After treatment,the main indexes of treatment and control groups werecompared: CRP were( 8. 15 ± 2. 67) and( 12. 04 ± 3. 08) mg·L~(-1),CD4~+were( 42. 53 ± 3. 29) % and( 36. 48 ± 3. 19) %,CD8~+were( 32. 07 ± 3. 27) % and( 27. 81 ± 3. 10) %,the differences were statistically significant( all P < 0. 05). There were no adverse reactions occurred during the treatment. Conclusion Pidotimod oral sodution combined with budesonide pressurised inhalation has a definitive clinical efficacy and safety in the treatment of children with RRTI,which can significantly improve the immune function of the children.
引文
[1]何玲,王松,符宗敏,等.儿童肺炎支原体肺炎后发生反复呼吸道感染的多因素分析[J].临床儿科杂志,2015,33(2):117-120.
[2]马力忠,王桂兰,梁桂明,等.免疫调节剂对小儿反复呼吸道感染临床症状及免疫功能的影响[J].中国妇幼保健,2016,31(2):414-415.
[3]吴海丽,李贤斌.气雾型布地奈德联合孟鲁司特钠治疗小儿咳嗽变异性哮喘疗效及对肺功能和血清炎症因子的影响[J].海南医学院学报,2016,22(5):467-469.
[4]中华医学会儿科学分会呼吸学组.反复呼吸道感染的临床概念和处理原则[J].中华儿科杂志,2008,46(2):108-110.
[2]马力忠,王桂兰,梁桂明,等.免疫调节剂对小儿反复呼吸道感染临床症状及免疫功能的影响[J].中国妇幼保健,2016,31(2):414-415.
[3]吴海丽,李贤斌.气雾型布地奈德联合孟鲁司特钠治疗小儿咳嗽变异性哮喘疗效及对肺功能和血清炎症因子的影响[J].海南医学院学报,2016,22(5):467-469.
[4]中华医学会儿科学分会呼吸学组.反复呼吸道感染的临床概念和处理原则[J].中华儿科杂志,2008,46(2):108-110.